Antibacterial and antifungal agents

Drug-Induced Liver Disease, Second Edition

Volumn , Issue , 2007, Pages 527-546

  Moseley, Richard H ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84877359440     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (280)

1. Trauner M, Boyer JL. Bile salt transporters: molecular characterization, function, and regulation. Physiol Rev 2003; 83:633-71.
2. Moseley RH. Sepsis and cholestasis. Clin Liver Dis 2004; 8:83-94.
3. Carson JL, Strom BL, Duff A, et al. Acute liver disease associated with erythromycins, sulfonamides, and tetracyclines. Ann Intern Med 1993; 119:576-83.
4. Sgro C, Clinard F, Ouazir K, et al. Incidence of drug-induced hepatic injuries: a French populationbased study. Hepatology 2002; 36:451-5.
5. de Abajo FJ, Montero D, Madurga M, Garcia Rodriguez LA. Acute and clinically relevant druginduced liver injury: a population based case-control study. Br J Clin Pharmacol 2004; 58:71-80.
6. Galan MV, Potts JA, Silverman AL, Gordon SC. Hepatitis in a United States tertiary referral center. J Clin Gastroenterol 2005; 39:64-7.
7. Meier Y, Cavallaro M, Roos M, et al. Incidence of drug-induced liver injury in medical inpatients. Eur J Clin Pharmacol 2005; 61:135-43.
8. Andrade RJ, Lucena MI, Fernandez MC, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129:512-21.
9. Bjornsson E, Jerlstad P, Bergqvist A, Olsson R. Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden. Scand J Gastroenterol 2005; 40:1095-101.
10. Bjornsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 2005; 42:481-9.
11. Parry MF. The pencillins. Med Clin North Am 1987; 71:1093-112.
12. Goldstein LI, Ishak KG. Hepatic injury associated with penicillin therapy. Arch Pathol 1974; 98:114-7.
13. Williams CN, Malatjalian DA. Severe penicillin-induced cholestasis in a 91-year-old woman. Dig Dis Sci 1981; 26:470-3.
14. Onate J, Montejo M, Aguirrebengoa K, Ruiz-Irastorza G, Gonzalez de Zarate P, Aguirre C. Hepatotoxicity associated with penicillin V therapy. Clin Infect Dis 1995; 20:474-5.
15. Andrade RJ, Guilarte J, Salmeron FJ, Lucena MI, Bellot V. Benzylpenicillin-induced prolonged cholestasis. Ann Pharmacother 2001; 35:783-4.
16. Cavanzo FJ, Garcia CF, Botero RC. Chronic cholestasis, paucity of bile ducts, red cell aplasia, and the Stevens-Johnson syndrome: an ampicillin-associated case. Gastroenterology 1990; 99:854-6.
17. Koklu S, Yuksel O, Filik L, Uskudar O, Altundag K, Altiparmak E. Recurrent cholestasis due to ampicillin. Ann Pharmacother 2003; 37:395-7.
18. Koklu S, Koksal AS, Asil M, Kiyici H, Coban S, Arhan M. Probable sulbactam/ampicillin-associated prolonged cholestasis. Ann Pharmacother 2004; 38:2055-8.
19. Garcia Rodriguez LA, Stricker BH, Zimmerman HJ. Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid. Arch Intern Med 1996; 156:1327-32.
20. Davies MH, Harrison RF, Elias E, Hubscher SG. Antibiotic-associated acute vanishing bile duct syndrome: a pattern associated with severe, prolonged, intrahepatic cholestasis. J Hepatol 1994; 20:112-6.
21. Miller WI, Souney PF, Chang JT. Hepatic dysfunction following nafcillin and cephalothin therapy in a patient with a history of oxacillin hepatitis. Clin Pharm 1983; 2:465-8.
22. Mazuryk H, Kastenberg D, Rubin R, Munoz SJ. Cholestatic hepatitis associated with the use of nafcillin. Am J Gastroenterol 1993; 88:1960-2.
23. Schuman R, Miskovitz P. Nafcillin-associated jaundice. Am J Gastroenterol 1994; 89:952.
24. Presti ME, Janney CG, Neuschwander-Tetri BA. Nafcillin-associated hepatotoxicity: report of a case and review of the literature. Dig Dis Sci 1996; 41:180-4.
25. Wilson FM, Belamaric J, Lauter CB, Lerner AM. Anicteric carbenicillin hepatitis. Eight episodes in four patients. JAMA 1975; 232:818-21.
26. Siegmund JB, Tarshis AM. Prolonged jaundice after dicloxacillin therapy. Am J Gastroenterol 1993; 88:1299-300.
27. Kleinman MS, Presberg JE. Cholestatic hepatitis after dicloxacillin-sodium therapy. J Clin Gastroenterol 1986; 8:77-8.
28. Saab S, Venkataramani A, Yao F. Possible granulomatous hepatitis after dicloxacillin therapy. J Clin Gastroenterol 1996; 22:163-4.
29. Olsson R, Wiholm BE, Sand C, Zettergren L, Hultcrantz R, Myrhed M. Liver damage from flucloxacillin, cloxacillin and dicloxacillin. J Hepatol 1992; 15:154-61.
30. Konikoff F, Alcalay J, Halevy J. Cloxacillin-induced cholestatic jaundice. Am J Gastroenterol 1986; 81:1082-3.
31. Pascual J, Orofino L, Marcen R, Quereda C, Ortuno J. Cloxacillin-induced cholestasis in a renal allograft patient with chronic hepatitis. Am J Gastroenterol 1990; 85:335-6.
32. Lotric S, Lejko-Zupanc T, Jereb M. Cloxacillin-induced cholestasis. Clin Infect Dis 1994; 19:981-2.
33. Goland S, Malnick SD, Gratz R, Feldberg E, Geltner D, Sthoeger ZM. Severe cholestatic hepatitis following cloxacillin treatment. Postgrad Med J 1998; 74:59-60.
34. Klein I, Tobias H. Oxacillin-associated hepatitis. Am J Gastroenterol 1976; 65:546.
35. Pollock AA, Berger SA, Simberkoff MS, Rahal JJ. Hepatitis associated with high-dose oxacillin therapy. Arch Intern Med 1978; 138:915-7.
36. Onorato IM, Axelrod JL. Hepatitis from intravenous high-dose oxacillin therapy: findings in an adult inpatient population. Ann Intern Med 1978; 89:497-500.
37. Bruckstein AH, Attia AA. Oxacillin hepatitis. Two patients with liver biopsy, and review of the literature. Am J Med 1978; 64:519-22.
38. Goldstein LI, Granoff M, Waisman J. Hepatic injury due to oxacillin administration. Am J Gastroenterol 1978; 70:171-4.
39. Halloran TJ, Clague MD. Hepatitis associated with high-dose oxacillin therapy. Arch Intern Med 1979; 139:376-7.
40. D’Angelo LJ. Oxacillin and hepatotoxicity. Ann Intern Med 1979; 90:442.
41. Tauris P, Jorgensen NF, Petersen CM, Albertsen K. Prolonged severe cholestasis induced by oxacillin derivatives. A report on two cases. Acta Med Scand 1985; 217:567-9.
42. Al-Homaidhi H, Abdel-Haq NM, El-Baba M, Asmar BI. Severe hepatitis associated with oxacillin therapy. South Med J 2002; 95:650-2.
43. Maraqa NF, Gomez MM, Rathore MH, Alvarez AM. Higher occurrence of hepatotoxicity and rash in patients treated with oxacillin, compared with those treated with nafcillin and other commonly used antimicrobials. Clin Infect Dis 2002; 34:50-4.
44. Saliba B, Herbert PN. Oxacillin hepatotoxicity in HIV-infected patients. Ann Intern Med 1994; 120:1048.
45. Aderka D, Livni E, Salamon F, Weinberger A, Pinkhas J. Use of macrophage inhibition factor and mast-cell degranulation tests for diagnosis of cloxacillin-induced cholestasis. Am J Gastroenterol 1986; 81:1084-6.
46. Horikawa M, Kato Y, Tyson CA, Sugiyama Y. Potential cholestatic activity of various therapeutic agents assessed by bile canalicular membrane vesicles isolated from rats and humans. Drug Metab Pharmacokinet 2003; 18:16-22.
47. Lobatto S, Dijkmans BA, Mattie H, Van Hooff JP. Flucloxacillin-associated liver damage. Neth J Med 1982; 25:47-8.
48. Bengtsson F, Floren CH, Hagerstrand I, Soderstrom C, Aberg T. Flucloxacillin-induced cholestatic liver damage. Scand J Infect Dis 1985; 17:125-8.
49. Turner IB, Eckstein RP, Riley JW, Lunzer MR. Prolonged hepatic cholestasis after flucloxacillin therapy. Med J Aust 1989; 151:701-5.
50. Fairley CK, McNeil JJ, Desmond P, et al. Risk factors for development of flucloxacillin associated jaundice. Br Med J 1993; 306:233-5.
51. Devereaux BM, Crawford DH, Purcell P, Powell LW, Roeser HP. Flucloxacillin associated cholestatic hepatitis. An Australian and Swedish epidemic? Eur J Clin Pharmacol 1995; 49:81-5.
52. Piotrowicz A, Polkey M, Wilkinson M. Ursodeoxycholic acid for the treatment of flucloxacillinassociated cholestasis. J Hepatol 1995; 22:119-20.
53. Eckstein RP, Dowsett JF, Lunzer MR. Flucloxacillin induced liver disease. Histopathological findings at biopsy and autopsy. Pathology 1993; 25:223-8.
54. Miros M, Kerlin P, Walker N, Harris O. Flucloxacillin induced delayed cholestatic hepatitis. Aust NZ J Med 1990; 20:251-3.
55. Koek GH, Stricker BH, Blok AP, Schalm SW, Desmet VJ. Flucloxacillin-associated hepatic injury. Liver 1994; 14:225-9.
56. Jick H, Derby LE, Dean AD, Henry DA. Flucloxacillin and cholestatic hepatitis. Med J Aust 1994; 160:525.
57. Derby LE, Jick H, Henry DA, Dean AD. Cholestatic hepatitis associated with flucloxacillin. Med J Aust 1993; 158:596-600.
58. George DK, Crawford DH. Antibacterial-induced hepatotoxicity. Incidence, prevention and management. Drug Saf 1996; 15:79-85.
59. Russmann S, Kaye JA, Jick SS, Jick H. Risk of cholestatic liver disease associated with flucloxacillin and flucloxacillin prescribing habits in the U.K.: cohort study using data from the U.K. General Practice Research Database. Br J Clin Pharmacol 2005; 60:76-82.
60. Lakehal F, Dansette PM, Becquemont L, et al. Indirect cytotoxicity of flucloxacillin toward human biliary epithelium via metabolite formation in hepatocytes. Chem Res Toxicol 2001; 14:694-701.
61. Carey MA, van Pelt FN. Immunochemical detection of flucloxacillin adduct formation in livers of treated rats. Toxicology 2005; 216:41-8.
62. Dowsett JF, Gillow T, Heagerty A, Radcliffe M, Toadi R, Isle I, Russell RC. Amoxycillin/clavulanic acid (Augmentin)-induced intrahepatic cholestasis. Dig Dis Sci 1989; 34:1290-3.
63. Stricker BH, Van den Broek JW, Keuning J, Eberhardt W, Houben HG, Johnson M, Blok AP. Cholestatic hepatitis due to antibacterial combination of amoxicillin and clavulanic acid (augmentin). Dig Dis Sci 1989; 34:1576-80.
64. Reddy KR, Brillant P, Schiff ER. Amoxicillin-clavulanate potassium-associated cholestasis. Gastroenterology 1989; 96:1135-41.
65. Schneider JE, Kleinman MS, Kupiec JW. Cholestatic hepatitis after therapy with amoxicillin/clavulanate potassium. NY State J Med 1989; 89:355-6.
66. Verhamme M, Ramboer C, Van de Bruaene P, Inderadjaja N. Cholestatic hepatitis due to an amoxycillin/clavulanic acid preparation. J Hepatol 1989; 9:260-4.
67. Silvain C, Fort E, Levillian P, et al. Granulomatous hepatitis due to combination of amoxicillin and clavulanic acid. Dig Dis Sci 1992; 37:150-2.
68. Larrey D, Vial T, Micaleff A, Babany G, Morichau-Beauchant M, Michel H, Benhamou JP. Hepatitis associated with amoxycillin-clavulanic acid combination report of 15 cases. Gut 1992; 33:368-71.
69. Thomson JA, Fairley CK, Ugoni AM, et al. Risk factors for the development of amoxycillin- clavulanic acid associated jaundice. Med J Aust 1995; 162:638-40.
70. Gresser U. Amoxicillin-clavulanic acid therapy may be associated with severe side effects-review of the literature. Eur J Med Res 2001; 6(4):139-49.
71. Ryley NG, Fleming KA, Chapman RW. Focal destructive cholangiopathy associated with amoxycillin/clavulanic acid (Augmentin). J Hepatol 1995; 23:278-82.
72. Richardet JP, Mallat A, Zafrani ES, Blazquez M, Bognel JC, Campillo B. Prolonged cholestasis with ductopenia after administration of amoxicillin/clavulanic acid. Dig Dis Sci 1999; 44:1997-2000.
73. Hebbard GS, Smith KG, Gibson PR, Bhathal PS. Augmentin-induced jaundice with a fatal outcome. Med J Aust 1992; 156:285-6.
74. Fontana RJ, Shakil AO, Greenson JK, Boyd I, Lee WM. Acute liver failure due to amoxicillin and amoxicillin/clavulanate. Dig Dis Sci 2005; 50:1785-90.
75. Chawla A, Kahn E, Yunis EJ, et al. Rapidly progressive cholestasis. An unusual reaction to amoxicillin/clavulanic acid therapy in a child. J Pediatr 2000; 136:121-3.
76. Smith LA, Ignacio JR, Winesett MP, et al. Vanishing bile duct syndrome: amoxicillin-clavulanic acid associated intra-hepatic cholestasis responsive to ursodeoxycholic acid. J Pediatr Gastroenterol Nutr 2005; 41:469-73.
77. Katsinelos P, Vasiliadis T, Xiarchos P, Patakiouta F, Christodoulou K, Pilpilidis I, Eugenidis N. Ursodeoxycholic acid (UDCA) for the treatment of amoxycillin-clavulanate potassium (Augmentin)-induced intra-hepatic cholestasis: report of two cases. Eur J Gastroenterol Hepatol 2000; 12:365-8.
78. Hautekeete ML, Horsmans Y, Van Waeyenberge C, et al. HLA association of amoxicillin- clavulanate-induced hepatitis. Gastroenterology 1999; 117:1181-6.
79. O’Donohue J, Oien KA, Donaldson P, Underhill J, Clare M, MacSween RN, Mills PR. Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut 2000; 47:717-20.
80. Berg P, Hahn EG. Hepatotoxic reactions induced by beta-lactamase inhibitors. Eur J Med Res 2001; 6:535-42.
81. Parry MF. The safety and tolerance of azlocillin. Arzneimittelforschung 1985; 35:1292-4.
82. Lang R, Lishner M, Ravid M. Adverse reactions to prolonged treatment with high doses of carbenicillin and ureidopenicillins. Rev Infect Dis 1991; 13:68-72.
83. Hargreaves JE, Herchline TE. Severe cholestatic jaundice caused by mezlocillin. Clin Infect Dis 1992; 15:179-80.
84. Quattropani C, Schneider M, Helbling A, Zimmermann A, Krahenbuhl S. Cholangiopathy after short-term administration of piperacillin and imipenem/cilastatin. Liver 2001; 21:213-6.
85. Ammann R, Neftel K, Hardmeier T, Reinhardt M. Cephalosporin-induced cholestatic jaundice. Lancet 1982; 2:336-7.
86. Eggleston SM, Belandres MM. Jaundice associated with cephalosporin therapy. Drug Intell Clin Pharm 1985; 19:553-5.
87. Bjornsson E, Olsson R. Acute liver injury due to loracarbef. J Hepatol 1997; 26:739-40.
88. Skoog SM, Smyrk TC, Talwalkar JA. Cephalexin-induced cholestatic hepatitis. J Clin Gastroenterol 2004; 38:833.
89. Shiffman ML, Keith FB, Moore EW. Pathogenesis of ceftriaxone-associated biliary sludge. In vitro studies of calcium-ceftriaxone binding and solubility. Gastroenterology 1990; 99:1772-8.
90. Johnson DF, Hall WH. Allergic hepatitis caused by propionyl erythromycin ester of lauryl sulfate. N Engl J Med 1961; 265:1200-2.
91. Reed C, Ritchie F. Toxic jaundice due to propionyl erythromycin ester lauryl sulphate (Ilosone). Med J Aust 1962; 49:810-2.
92. Tolman KG, Sannella JJ, Freston JW. Chemical structure of erythromycin and hepatotoxicity. Ann Intern Med 1974; 81:58-60.
93. Zafrani ES, Ishak KG, Rudzki C. Cholestatic and hepatocellular injury associated with erythromycin esters: report of nine cases. Dig Dis Sci 1979; 24:385-96.
94. Viteri AL, Greene JF, Jr., Dyck WP. Erythromycin ethylsuccinate-induced cholestasis. Gastroenterology 1979; 76:1007-8.
95. Keeffe EB, Reis TC, Berland JE. Hepatotoxicity to both erythromycin estolate and erythromycin ethylsuccinate. Dig Dis Sci 1982; 27:701-4.
96. Diehl AM, Latham P, Boitnott JK, Mann J, Maddrey WC. Cholestatic hepatitis from erythromycin ethylsuccinate. Report of two cases. Am J Med 1984; 76:931-4.
97. Inman WH, Rawson NS. Erythromycin estolate and jaundice. Br Med J 1983; 286:1954-5.
98. Avila P, Capella D, Laporte JR, Moreno V. Which salt of erythromycin is most hepatotoxic? Lancet 1988; 1:1104.
99. Derby LE, Jick H, Henry DA, Dean AD. Erythromycin-associated cholestatic hepatitis. Med J Aust 1993; 158:600-2.
100. Geubel AP, Nakad A, Rahier J, Dive C. Prolonged cholestasis and disappearance of interlobular bile ducts following chlorpropamide and erythromycin ethylsuccinate. Case of drug interaction? Liver 1988; 8:350-3.
101. Degott C, Feldmann G, Larrey D. Drug-induced prolonged cholestasis in adults: a histological semiquantitative study demonstrating progressive ductopenia. Hepatology 1992; 15:244-51.
102. Lazarczyk DA, Duffy MC. Erythromycin-induced primary biliary cirrhosis. Dig Dis Sci 2000; 45:1115-8.
103. Gholson CF, Warren GH. Fulminant hepatic failure associated with intravenous erythromycin lactobionate. Arch Intern Med 1990; 150:215-6.
104. Longo G, Valenti C, Gandini G, Ferrara L, Bertesi M, Emilia G. Azithromycin-induced intrahepatic cholestasis. Am J Med 1997; 102:217-8.
105. Cascaval RI, Lancaster DJ. Hypersensitivity syndrome associated with azithromycin. Am J Med 2001; 110:330-1.
106. Chandrupatla S, Demetris AJ, Rabinovitz M. Azithromycin-induced intrahepatic cholestasis. Dig Dis Sci 2002; 47:2186-8.
107. Sturgill MG, Rapp RP. Clarithromycin: review of a new macrolide antibiotic with improved microbiologic spectrum and favorable pharmacokinetic and adverse effect profiles. Ann Pharmacother 1992; 26:1099-108.
108. Yew WW, Chau CH, Lee J, Leung CW. Cholestatic hepatitis in a patient who received clarithromycin therapy for a Mycobacterium chelonae lung infection. Clin Infect Dis 1994; 18:1025-6.
109. Brown BA, Wallace RJ, Griffith DE, Girard W. Clarithromycin-induced hepatotoxicity. Clin Infect Dis 1995; 20:1073-4.
110. Fox JC, Szyjkowski RS, Sanderson SO, Levine RA. Progressive cholestatic liver disease associated with clarithromycin treatment. J Clin Pharmacol 2002; 42:676-80.
111. Shaheen N, Grimm IS. Fulminant hepatic failure associated with clarithromycin. Am J Gastroenterol 1996; 91:394-5.
112. Masia M, Gutierrez F, Jimeno A, Navarro A, Borras J, Matarredona J, Martin-Hidalgo A. Fulminant hepatitis and fatal toxic epidermal necrolysis (Lyell disease) coincident with clarithromycin administration in an alcoholic patient receiving disulfiram therapy. Arch Intern Med 2002; 162:474-6.
113. Christopher K, Hyatt PA, Horkan C, Yodice PC. Clarithromycin use preceding fulminant hepatic failure. Am J Gastroenterol 2002; 97:489-90.
114. Tietz A, Heim MH, Eriksson U, Marsch S, Terracciano L, Krahenbuhl S. Fulminant liver failure associated with clarithromycin. Ann Pharmacother 2003; 37:57-60.
115. Nguyen M, Chung EP. Telithromycin: the first ketolide antimicrobial. Clin Ther 2005; 27:1144-63.
116. Peters TS. Do preclinical testing strategies help predict human hepatotoxic potentials? Toxicol Pathol 2005; 33:146-54.
117. Clay KD, Hanson JS, Pope SD, Rissmiller RW, Purdum PP III, Banks PM. Brief communication:severe hepatotoxicity of telithromycin: three case reports and literature review. Ann Intern Med 2006; 144:415-20.
118. Yamaguchi S, Zhao YL, Nadai M. Involvement of the drug transporters P-glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrob Agents Chemother 2006; 50:80-7.
119. Gaeta GB, Utili R, Adinolfi LE, Abernathy CO, Giusti G. Characterization of the effects of erythromycin estolate and erythromycin base on the excretory function of the isolated rat liver. Toxicol Appl Pharmacol 1985; 80:185-92.
120. Kostrubsky VE, Strom SC, Hanson J, et al. Evaluation of hepatotoxic potential of drugs by inhibition of bile-acid transport in cultured primary human hepatocytes and intact rats. Toxicol Sci 2003; 76:220-8.
121. Pessayre D, Larrey D, Funck-Brentano C, Benhamou JP. Drug interactions and hepatitis produced by some macrolide antibiotics. J Antimicrob Chemother 1985; 16(Suppl. A):181-94.
122. Westphal JF, Brogard JM. Antibacterials and antifungal agents. In: Kaplowitz N, DeLeve LD, eds. Drug-Induced Liver Disesase. New York: Marcel Dekker, 2003.
123. Dujovne CA, Chan CH, Zimmerman HJ. Sulfonamide hepatic injury. Review of the literature and report of a case due to sulfamethoxazole. N Engl J Med 1967; 277:785-8.
124. Gordin FM, Simon GL, Wofsy CB, Mills J. Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1984; 100:495-9.
125. Espiritu CR, Kim TS, Levine RA. Granulomatous hepatitis associated with sulfadimethoxine hypersensitivity. JAMA 1967; 202:985-8.
126. Callen JP, Soderstrom RM. Granulomatous hepatitis associated with salicylazosulfapyridine therapy. South Med J 1978; 71:1159-60.
127. Lazar HP, Murphy RL, Phair JP. Fansidar and hepatic granulomas. Ann Intern Med 1985; 102:722.
128. Zaman F, Ye G, Abreo KD, Latif S, Zibari GB. Successful orthotopic liver transplantation after trimethoprim-sulfamethoxazole associated fulminant liver failure. Clin Transplant 2003; 17:461-4.
129. Alberti-Flor JJ, Hernandez ME, Ferrer JP, Howell S, Jeffers L. Fulminant liver failure and pancreatitis associated with the use of sulfamethoxazole-trimethoprim. Am J Gastroenterol 1989; 84:1577-9.
130. Zitelli BJ, Alexander J, Taylor S, et al. Fatal hepatic necrosis due to pyrimethamine-sulfadoxine (Fansidar). Ann Intern Med 1987; 106:393-5.
131. Ransohoff DF, Jacobs G. Terminal hepatic failure following a small dose of sulfamethoxazole- trimethoprim. Gastroenterology 1981; 80:816-9.
132. Yao F, Behling CA, Saab S, Li S, Hart M, Lyche KD. Trimethoprim-sulfamethoxazole-induced vanishing bile duct syndrome. Am J Gastroenterol 1997; 92:167-9.
133. Altraif I, Lilly L, Wanless IR, Heathcote J. Cholestatic liver disease with ductopenia (vanishing bile duct syndrome) after administration of clindamycin and trimethoprim-sulfamethoxazole. Am J Gastroenterol 1994; 89:1230-4.
134. Kowdley KV, Keeffe EB, Fawaz KA. Prolonged cholestasis due to trimethoprim sulfamethoxazole. Gastroenterology 1992; 102:2148-50.
135. Abi-Mansur P, Ardiaca MC, Allam C, Shamma’a M. Trimethoprim-sulfamethoxazole-induced cholestasis. Am J Gastroenterol 1981; 76:356-9.
136. Nair SS, Kaplan JM, Levine LH, Geraci K. Trimethoprim-sulfamethoxazole-induced intrahepatic cholestasis. Ann Intern Med 1980; 92:511-2.
137. Munoz SJ, Martinez-Hernandez A, Maddrey WC. Intrahepatic cholestasis and phospholipidosis associated with the use of trimethoprim-sulfamethoxazole. Hepatology 1990; 12:342-7.
138. Thies PW, Dull WL. Trimethoprim-sulfamethoxazole-induced cholestatic hepatitis: inadvertent rechallenge. Arch Intern Med 1984; 144:1691-2.
139. Wolkenstein P, Carriere V, Charue D, et al. A slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome. Pharmacogenetics 1995; 5:255-8.
140. O’Neil WM, MacArthur RD, Farrough MJ, et al. Acetylator phenotype and genotype in HIV-infected patients with and without sulfonamide hypersensitivity. J Clin Pharmacol 2002; 42:613-9.
141. Alfirevic A, Stalford AC, Vilar FJ, Wilkins EG, Park BK, Pirmohamed M. Slow acetylator phenotype and genotype in HIV-positive patients with sulphamethoxazole hypersensitivity. Br J Clin Pharmacol 2003; 55:158-65.
142. Dowling HF, Lepper MH. Hepatic reactions to tetracycline. JAMA 1964; 188:307-9.
143. Zimmerman HJ. Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver. 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 1999.
144. Combes B, Whalley PJ, Adams RH. Tetracycline and the liver. Prog Liver Dis 1972; 4:589-96.
145. Whalley PJ, Adams RH, Combes B. Tetracycline toxicity in pregnancy. JAMA 1964; 189:357-62.
146. Allen ES, Brown WE. Hepatic toxicity of tetracycline in pregnancy. Am J Obstet Gynecol 1966; 95:12-8.
147. Schultz JC, Adamson JS, Workman WW, Norman TD. Fatal liver disease after intravenous administration of tetracycline in high dosage. N Engl J Med 1963; 269:999-1004.
148. Freneaux E, Labbe G, Letteron P, et al. Inhibition of the mitochondrial oxidation of fatty acids by tetracycline in mice and in man: possible role in microvesicular steatosis induced by this antibiotic. Hepatology 1988; 8:1056-62.
149. Letteron P, Sutton A, Mansouri A, Fromenty B, Pessayre D. Inhibition of microsomal triglyceride transfer protein: another mechanism for drug-induced steatosis in mice. Hepatology 2003; 38:133-40.
150. Bjornsson E, Lindberg J, Olsson R. Liver reactions to oral low-dose tetracyclines. Scand J Gastroenterol 1997; 32:390-5.
151. Hunt CM, Washington K. Tetracycline-induced bile duct paucity and prolonged cholestasis. Gastroenterology 1994; 107:1844-7.
152. Westermann GW, Bohm M, Bonsmann G, Rahn KH, Kisters K. Chronic intoxication by doxycycline use for more than 12 years. J Intern Med 1999; 246(6):591-2.
153. Burette A, Finet C, Prigogine T, De Roy G, Deltenre M. Acute hepatic injury associated with minocycline. Arch Intern Med 1984; 144:1491-2.
154. Davies MG, Kersey PJ. Acute hepatitis and exfoliative dermatitis associated with minocycline. Br Med J 1989; 298:1523-4.
155. Malcolm A, Heap TR, Eckstein RP, Lunzer MR. Minocycline-induced liver injury. Am J Gastroenterol 1996; 91:1641-3.
156. Gough A, Chapman S, Wagstaff K, Emery P, Elias E. Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. Br Med J 1996; 312:169-72.
157. Teitelbaum JE, Perez-Atayde AR, Cohen M, Bousvaros A, Jonas MM. Minocycline-related autoimmune hepatitis: case series and literature review. Arch Pediatr Adolesc Med 1998; 152:1132-6.
158. Crosson J, Stillman MT. Minocycline-related lupus erythematosus with associated liver disease. J Am Acad Dermatol 1997; 36:867-8.
159. Golstein PE, Deviere J, Cremer M. Acute hepatitis and drug-related lupus induced by minocycline treatment. Am J Gastroenterol 1997; 92:143-6.
160. Bhat G, Jordan J, Jr., Sokalski S, Bajaj V, Marshall R, Berkelhammer C. Minocycline-induced hepatitis with autoimmune features and neutropenia. J Clin Gastroenterol 1998; 27:74-5.
161. Goldstein NS, Bayati N, Silverman AL, Gordon SC. Minocycline as a cause of drug-induced autoimmune hepatitis. Report of four cases and comparison with autoimmune hepatitis. Am J Clin Pathol 2000; 114:591-8.
162. Nietsch HH, Libman BS, Pansze TW, Eicher JN, Reeves JR, Krawitt EL. Minocycline-induced hepatitis. Am J Gastroenterol 2000; 95:2993-5.
163. Min DI, Burke PA, Lewis WD, Jenkins RL. Acute hepatic failure associated with oral minocycline: a case report. Pharmacotherapy 1992; 12:68-71.
164. Boudreaux JP, Hayes DH, Mizrahi S, Hussey J, Regenstein F, Balart L. Fulminant hepatic failure, hepatorenal syndrome, and necrotizing pancreatitis after minocycline hepatotoxicity. Transplant Proc 1993; 25:1873.
165. Pohle T, Menzel J, Domschke W. Minocycline and fulminant hepatic failure necessitating liver transplantation. Am J Gastroenterol 2000; 95:560-1.
166. Lawrenson RA, Seaman HE, Sundstrom A, Williams TJ, Farmer RD. Liver damage associated with minocycline use in acne: a systematic review of the published literature and pharmacovigilance data. Drug Saf 2000; 23:333-49.
167. Maddrey WC. Drug-induced hepatotoxicity: 2005. J Clin Gastroenterol 2005; 39(Suppl. 2):S83-9.
168. Kaufmann D, Pichler W, Beer JH. Severe episode of high fever with rash, lymphadenopathy, neutropenia, and eosinophilia after minocycline therapy for acne. Arch Intern Med 1994; 154:1983-4.
169. Seaman HE, Lawrenson RA, Williams TJ, MacRae KD, Farmer RD. The risk of liver damage associated with minocycline: a comparative study. J Clin Pharmacol 2001; 41:852-60.
170. Liu ZX, Kaplowitz N. Immune-mediated drug-induced liver disease. Clin Liver Dis 2002; 6:755-74.
171. Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E, Tigecycline 301 Study Group, Tigecycline 306 Study Group. The efficacy and safety of tigecycline for the treatment of complicated intraabdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005; 41(Suppl. 5):S354-67.
172. Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E, Tigecycline 300 cSSSI Study Group, Tigecycline 305 cSSSI Study Group. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin- aztreonam. Clin Infect Dis 2005; 41(Suppl. 5):S341-53.
173. Owens RC, Jr., Ambrose PG. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis 2005; 41(Suppl. 2):S144-57.
174. Lopez-Navidad A, Domingo P, Cadafalch J, et al. Norfloxacin-induced hepatotoxicity. J Hepatol 1990; 11:277-8.
175. Blum A. Oflxacin-induced acute severe hepatitis. South Med J 1991; 84:1158.
176. Villeneuve JP, Davies C, Cote J. Suspected ciprofloxacin-induced hepatotoxicity. Ann Pharmacother 1995; 29:257-9.
177. Sherman O, Beizer JL. Possible ciprofloxacin induced cholestatic jaundice. Ann Pharmacother 1994; 28:1162-4.
178. Hautekeete ML. Cholestatic hepatitis related to quinolones: a report of two cases. J Hepatol 1995; 23:759-60.
179. Labowitz JK, Silverman WB. Cholestatic jaundice induced by ciprofloxacin. Dig Dis Sci 1997; 42:192-4.
180. Lucena MI, Andrade RJ, Sanchez-Martinez H, Perez-Serrano JM, Gomez-Outes A. Norfloxacininduced cholestatic jaundice. Am J Gastroenterol 1998; 93:2309-11.
181. Soto S, Lopez-Roses L, Avila S, Lancho A, Gonzalez A, Santos E, Urraca B. Moxifloxacin-induced acute liver injury. Am J Gastroenterol 2002; 97:1853-4.
182. Bataille L, Rahier J, Geubel A. Delayed and prolonged cholestatic hepatitis with ductopenia after long-term ciprofloxacin therapy for Crohn’s disease. J Hepatol 2002; 37:696-9.
183. Cheung O, Chopra K, Yu T, Nalesnik MA, Amin S, Shakil AO. Gatifloxacin-induced hepatotoxicity and acute pancreatitis. Ann Intern Med 2004; 140:73-4.
184. Grassmick BK, Lehr VT, Sundareson AS. Fulminant hepatic failure possibly related to ciprofloxacin. Ann Pharmacother 1992; 26:636-9.
185. Fuchs S, Simon Z, Brezin M. Fatal hepatic failure associated with ciprofloxacin. Lancet 1994; 343:738-9.
186. Coleman CI, Spencer JV, Chung JO, Reddy P. Possible gatifloxacin-induced fulminant hepatic failure. Ann Pharmacother 2002; 36:1162-7.
187. Zimpfer A, Propst A, Mikuz G, Vogel W, Terracciano L, Stadlmann S. Ciprofloxacin-induced acute liver injury: case report and review of literature. Virchows Arch 2004; 444:87-9.
188. Lucena MI, Andrade RJ, Rodrigo L, et al. Trovafloxacin-induced acute hepatitis. Clin Infect Dis 2000; 30:400-1.
189. Chen HJ, Bloch KJ, Maclean JA. Acute eosinophilic hepatitis from trovafloxacin. N Engl J Med 2000; 342:359-60.
190. Lazarczyk DA, Goldstein NS, Gordon SC. Trovafloxacin hepatotoxicity. Dig Dis Sci 2001; 46:925-6.
191. Bertino J, Jr., Fish D, Bertino J, Fish D. The safety profile of the fluoroquinolones. Clin Ther 2000; 22:798-817.
192. Liguori MJ, Anderson LM, Bukofzer S, et al. Microarray analysis in human hepatocytes suggests a mechanism for hepatotoxicity induced by trovafloxacin. Hepatology 2005; 41:177-86.
193. Buchweitz JP, Ganey PE, Bursian SJ, Roth RA. Underlying endotoxemia augments toxic responses to chlorpromazine: is there a relationship to drug idiosyncrasy? J Pharmacol Exp Ther 2002; 300:460-7.
194. Roth RA, Luyendyk JP, Maddox JF, Ganey PE. Inflammation and drug idiosyncrasy-is there a connection? J Pharmacol Exp Ther 2003; 307:1-8.
195. Ganey PE, Luyendyk JP, Maddox JF, Roth RA. Adverse hepatic drug reactions: inflammatory episodes as consequence and contributor. Chem Biol Interact 2004; 150:35-51.
196. Waring JF, Liguori MJ, Luyendyk JP, et al. Microarray analysis of LPS potentiation of trovafloxacininduced liver injury in rats suggests a role for proinflammatory chemokines and neutrophils. J Pharmacol Exp Ther 2006; 316:1080-7.
197. Cadle RM, Mansouri MD, Darouiche RO. Vancomycin-induced elevation of liver enzyme levels. Ann Pharmacother 2006; 40:1186-9.
198. D’Arcy PF. Nitrofurantoin. Drug Intell Clin Pharm 1985; 19:540-7.
199. Goldstein LI, Ishak KG, Burns W. Hepatic injury associated with nitrofurantoin therapy. Am J Dig Dis 1974; 19:987-98.
200. Sharp JR, Ishak KG, Zimmerman HJ. Chronic active hepatitis and severe hepatic necrosis associated with nitrofurantoin. Ann Intern Med 1980; 92:14-19.
201. Black M, Rabin L, Schatz N. Nitrofurantoin-induced chronic active hepatitis. Ann Intern Med 1980; 92:62-4.
202. Sippel PJ, Agger WA. Nitrofurantoin-induced granulomatous hepatitis. Urology 1981; 18:177-8.
203. Stricker BH, Blok AP, Claas FH, Van Parys GE, Desmet VJ. Hepatic injury associated with the use of nitrofurans: a clinicopathological study of 52 reported cases. Hepatology 1988; 8:599-606.
204. Klemola H, Penttila O, Runeberg L, Tallqvist G. Anicteric liver damage during nitrofurantoin medication. Scand J Gastroenterol 1975; 10:501-5.
205. Fagrell B, Strandberg I, Wengle B. A nitrofurantoin-induced disorder simulating chronic active hepatitis. A case report. Acta Med Scand 1976; 199:237-9.
206. Stromberg A, Wengle B. Chronic active hepatitis induced by nitrofurantoin. Br Med J 1976; 2:174-5.
207. Iwarson S, Lindberg J, Lundin P. Nitrofurantoin-induced chronic liver disease. Clinical course and outcome of five cases. Scand J Gastroenterol 1979; 14:497-502.
208. Holmberg L, Boman G, Bottiger LE, Eriksson B, Spross R, Wessling A. Adverse reactions to nitrofurantoin. Analysis of 921 reports. Am J Med 1980; 69:733-8.
209. Paiva LA, Wright PJ, Koff RS. Long-term hepatic memory for hypersensitivity to nitrofurantoin. Am J Gastroenterol 1992; 87:891-3.
210. Engel JJ, Vogt TR, Wilson DE. Cholestatic hepatitis after administration of furan derivatives. Arch Intern Med 1975; 135:733-5.
211. Merino G, Jonker JW, Wagenaar E, van Herwaarden AE, Schinkel AH. The breast cancer resistance protein (BCRP/ABCG2) affects pharmacokinetics, hepatobiliary excretion, and milk secretion of the antibiotic nitrofurantoin. Mol Pharmacol 2005; 67:1758-64.
212. Merino G, van Herwaarden AE, Wagenaar E, Jonker JW, Schinkel AH. Sex-dependent expression and activity of the ATP-binding cassette transporter breast cancer resistance protein (BCRP/ABCG2) in liver. Mol Pharmacol 2005; 67:1765-71.
213. Vavricka SR, Van Montfoort J, Ha HR, Meier PJ, Fattinger K. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology 2002; 36:164-72.
214. Tirona RG, Leake BF, Wolkoff AW, Kim RB. Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther 2003; 304:223-8.
215. Acocella G, Nicolis FB, Tenconi LT. The effect of an intravenous infusion of rifamycin SV on the excretion of bilirubin, bromsulphalein and indocyanine green in man. Gastroenterology 1965; 49:521-5.
216. Galeazzi R, Lorenzini I, Orlandi F. Rifampicin-induced elevation of serum bile acids in man. Dig Dis Sci 1980; 25:108-12.
217. Marschall HU, Wagner M, Zollner G, et al. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology 2005; 129:476-85.
218. Prince MI, Burt AD, Jones DE. Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. Gut 2002; 50:436-9.
219. Elmore M, Rissing JP, Rink L, Brooks GF. Clindamycin-associated hepatotoxicity. Am J Med 1974; 57:627-30.
220. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI, Daptomycin 98-01 and 99-01 Investigators. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004; 38:1673-81.
221. Echevarria K, Datta P, Cadena J, Lewis JS. Severe myopathy and possible hepatotoxicity related to daptomycin. J Antimicrob Chemother 2005; 55:599-600.
222. Stevens DL, Dotter B, Madaras-Kelly K. A review of linezolid: the first oxazolidinone antibiotic. Expert Rev Anti Infect Ther 2004; 2:51-9.
223. Rubinstein E, Prokocimer P, Talbot GH. Safety and tolerability of quinupristin/dalfopristin:administration guidelines. J Antimicrob Chemother 1999; 44:37-46.
224. Linden PK, Bompart F, Gray S, Talbot GH. Hyperbilirubinemia during quinupristin-dalfopristin therapy in liver transplant recipients: correlation with available liver biopsy results. Pharmacotherapy 2001; 21:661-8.
225. Carnecchia BM, Kurtzke JF. Fatal toxic reaction to amphotericin B in cryptococcal meningoencephalitis. Ann Intern Med 1960; 53:1027-36.
226. Miller MA. Reversible hepatotoxicity related to amphotericin B. Can Med Assoc J 1984; 131:1245-7.
227. Gill J, Sprenger HR, Ralph ED, Sharpe MD. Hepatotoxicity possibly caused by amphotericin B. Ann Pharmacother 1999; 33:683-5.
228. Meunier F, Prentice HG, Ringden O. Liposomal amphotericin B [AmBisome]: safety data from a phase II/III clinical trial. J Antimicrob Chemother 1991; 28(Suppl. B):83-91.
229. Ellis M, Shamoon A, Gorka W, Zwaan F, al-Ramadi B. Severe hepatic injury associated with lipid formulations of amphotericin B. Clin Infect Dis 2001; 32:E87-9.
230. Fischer MA, Winkelmayer WC, Rubin RH, Avorn J. The hepatotoxicity of antifungal medications in bone marrow transplant recipients. Clin Infect Dis 2005; 41:301-7.
231. Wingard JR, Leather H. Hepatotoxicity associated with antifungal therapy after bone marrow transplantation. Clin Infect Dis 2005; 41:308-10.
232. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347:2020-9.
233. Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39:1563-71.
234. Bennett JE. Echinocandins for candidemia in adults with neutropenia. N Engl J Med 2006; 355:1154-9.
235. Garcia Rodriguez LA, Duque A, Castellsague J, Perez-Gutthann S, Stricker BH. A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs. Br J Clin Pharmacol 1999; 48:847-52.
236. Bradbury BD, Jick SS. Itraconazole and fluconazole and certain rare, serious adverse events. Pharmacotherapy 2002; 22:697-700.
237. Stricker BH, Blok AP, Bronkhorst FB, Van Parys GE, Desmet VJ. Ketoconazole-associated hepatic injury. A clinicopathological study of 55 cases. J Hepatol 1986; 3:399-406.
238. Janssen PA, Symoens JE. Hepatic reactions during ketoconazole treatment. Am J Med 1983; 74:80-5.
239. Chien RN, Yang LJ, Lin PY, Liaw YF. Hepatic injury during ketoconazole therapy in patients with onychomycosis: a controlled cohort study. Hepatology 1997; 25:103-7.
240. Lewis JH, Zimmerman HJ, Benson GD, Ishak KG. Hepatic injury associated with ketoconazole therapy. Analysis of 33 cases. Gastroenterology 1984; 86:503-13.
241. Duarte PA, Chow CC, Simmons F, Ruskin J. Fatal hepatitis associated with ketoconazole therapy. Arch Intern Med 1984; 144:1069-70.
242. Bercoff E, Bernuau J, Degott C, et al. Ketoconazole-induced fulminant hepatitis. Gut 1985; 26:636-8.
243. Lake-Bakaar G, Scheuer PJ, Sherlock S. Hepatic reactions associated with ketoconazole in the United Kingdom. Br Med J 1987; 294:419-22.
244. Kim T-H, Kim B-H, Kim Y-W, et al. Liver cirrhosis developed after ketoconazole-induced acute hepatic injury. J Gastroenterol Hepatol 2003; 18:1426-9.
245. Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. N Engl J Med 1994; 330:263-72.
246. Munoz P, Moreno S, Berenguer J, Bernaldo de Quiros JCL, Bouza E. Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome. Arch Intern Med 1991; 151:1020-1.
247. Franklin IM, Elias E, Hirsch C. Fluconazole-induced jaundice. Lancet 1990; 336:565.
248. Wells C, Lever AM. Dose-dependent fluconazole hepatotoxicity proven on biopsy and rechallenge. J Infect 1992; 24:111-2.
249. Jacobson MA, Hanks DK, Ferrel LD. Fatal acute hepatic necrosis due to fluconazole. Am J Med 1994; 96:188-90.
250. Trujillo MA, Galgiani JN, Sampliner RE. Evaluation of hepatic injury arising during fluconazole therapy. Arch Intern Med 1994; 154:102-4.
251. Gearhart MO. Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity. Ann Pharmacother 1994; 28:1177-81.
252. Bronstein JA, Gros P, Hernandez E, Larroque P, Molinie C. Fatal acute hepatic necrosis due to dosedependent fluconazole hepatotoxicity. Clin Infect Dis 1997; 25:1266-7.
253. Schottker B, Dosch A, Kraemer DM. Severe hepatotoxicity after application of desloratadine and fluconazole. Acta Haematol 2003; 110:43-4.
254. Guillaume MP, De Prez C, Cogan E. Subacute mitochondrial liver disease in a patient with AIDS:possible relationship to prolonged fluconazole administration. Am J Gastroenterol 1996; 91:165-8.
255. Tucker RM, Haq Y, Denning DW, Stevens DA. Adverse events associated with itraconazole in 189 patients on chronic therapy. J Antimicrob Chemother 1990; 26:561-6.
256. Hay RJ. Risk/benefit ratio of modern antifungal therapy: focus on hepatic reactions. J Am Acad Dermatol 1993; 29:S50-4.
257. Lavrijsen AP, Balmus KJ, Nugteren-Huying WM, Roldaan AC, van’t Wout JW, Stricker BH. Hepatic injury associated with itraconazole. Lancet 1992; 340:251-2.
258. Gallardo-Quesada S, Luelmo-Aguilar J, Guanyabens-Calvet C. Hepatotoxicity associated with itraconazole. Int J Dermatol 1995; 34:589.
259. Adriaenssens B, Roskams T, Steger P, Van Steenbergen W. Hepatotoxicity related to itraconazole:report of three cases. Acta Clin Belg 2001; 56:364-9.
260. Gupta AK, Chwetzoff E, Del Rosso J, Baran R. Hepatic safety of itraconazole. J Cutan Med Surg 2002; 6:210-3.
261. Potoski BA, Brown J. The safety of voriconazole. Clin Infect Dis 2002; 35:1273-5.
262. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003; 36:630-7.
263. Spellberg B, Rieg G, Bayer A, Edwards JE, Jr. Lack of cross-hepatotoxicity between fluconazole and voriconazole. Clin Infect Dis 2003; 36:1091-3.
264. Hall M, Monka C, Krupp P, O’Sullivan D. Safety of oral terbinafine: results of a postmarketing surveillance study in 25,884 patients. Arch Dermatol 1997; 133:1213-9.
265. Zapata Garrido AJ, Romo AC, Padilla FB. Terbinafine hepatotoxicity. A case report and review of literature. Ann Hepatol 2003; 2:47-51.
266. Fernandes NF, Geller SA, Fong TL. Terbinafine hepatotoxicity: case report and review of the literature. Am J Gastroenterol 1998; 93:459-60.
267. Gupta AK, del Rosso JQ, Lynde CW, Brown GH, Shear NH. Hepatitis associated with terbinafine therapy: three case reports and a review of the literature. Clin Exp Dermatol 1998; 23:64-7.
268. Lazaros GA, Papatheodoridis GV, Delladetsima JK, Tassopoulos NC. Terbinafine-induced cholestatic liver disease. J Hepatol 1996; 24:753-6.
269. van’t Wout JW, Herrmann WA, de Vries RA, Stricker BH. Terbinafine-associated hepatic injury. J Hepatol 1994; 21:115-7.
270. Lowe G, Green C, Jennings P. Hepatitis associated with terbinafine treatment. Br Med J 1993; 306:248.
271. Agarwal K, Manas DM, Hudson M. Terbinafine and fulminant hepatic failure. N Engl J Med 1999; 340:1292-3.
272. Mallat A, Zafrani ES, Metreau JM, Dhumeaux D. Terbinafine-induced prolonged cholestasis with reduction of interlobular bile ducts. Dig Dis Sci 1997; 42:1486-8.
273. Anania FA, Rabin L. Terbinafine hepatotoxicity resulting in chronic biliary ductopenia and portal fibrosis. Am J Med 2002; 112:741-2.
274. Ajit C, Suvannasankha A, Zaeri N, Munoz SJ. Terbinafine-associated hepatotoxicity. Am J Med Sci 2003; 325:292-5.
275. Vermes A, Guchelaar HJ, Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother 2000; 46:171-9.
276. Record CO, Skinner JM, Sleight P, Speller DC. Candida endocarditis treated with 5-fluorocytosine. Br Med J 1971; 1:262-4.
277. Libbrecht L, Meerman L, Kuipers F, Roskams T, Desmet V, Jansem P. Liver pathology and hepatocarcinogenesis in a long-term mouse model of erythropoietic protoporphyria. J Pathol 2003; 199:191-200.
278. Chiprut RO, Viteri A, Jamroz C, Dyck WP. Intrahepatic cholestasis after griseofulvin administration. Gastroenterology 1976; 70:1141-3.
279. Berman A, Franklin RL. Precipitation of acute intermittent porphyria by griseofulvin therapy. JAMA 1965; 192:1005-7.
280. Song JC, Deresinski S. Hepatotoxicity of antifungal agents. Curr Opin Investig Drugs 2005; 6:170-7.